Data / Form D filings / Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc.: Form D filings
Imbria Pharmaceuticals, Inc., a biotechnology company in Boston, MA, filed 4 Form D notices with the SEC between 2018 and 2025. The latest, on December 16, 2025, reports $66.7 million sold of a $144.2 million offering to 10 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 265 FRANKLIN STREET, SUITE #1702, Boston, MA, 02110
- Phone
- (917) 657-5069
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1745672
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 16, 2025 | Amendment | $144,195,814 | $66,695,817 | $77,499,997 | 10 | Mar 10, 2025 | sec.gov |
| Apr 1, 2025 | New notice | $124,195,815 | $59,195,818 | $64,999,997 | 8 | Mar 10, 2025 | sec.gov |
| Jul 2, 2020 | New notice | $80,734,932 | $40,734,932 | $40,000,000 | 4 | Jun 22, 2020 | sec.gov |
| Jul 9, 2018 | New notice | $40,249,995 | $40,249,995 | 3 | Jul 2, 2018 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Pavan Cheruvu | Director | |
| Charles Dunn | Director | |
| Alvin Shih | Executive Officer, Director | |
| Luse Rebecca | Director | |
| Ken Horne | Director | |
| Komal Joshi | Executive Officer | |
| Andrew Levin | Director | |
| Zina Affas Besse | Director |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Dec 15, 2025 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Imbria Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.